Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VERT moved away the stock will go up usually
CSTI and VERT notorious short sellers both lowering offer.
cool. good luck. i hope it is thin and runs to .10 !!!!
Only the lowest offers are shown through each market maker on level 2. so if .235 through Vert gets taken out there could be an order for shares at .0239. You wont see it until it is the lowest through that MM.
amen to that d-trdr
ATDF is the problem today. Might be a short seller. Constantly lowering offer and showing size.
Anxious seller through ATDF keeps dropping low offer.
Market Makers intentionally show size on the offer to try to make small investors think it will be difficult to break through the wall. This should run on news
MM wall at.02. News should come soon I bet and they are trying to keep it down and gather cheap shares on the bid side
can u give me a link to where you find that info please?
CEO can only put out news, he can't make it up or rush it along. Mother nature is involved with pressure and water forcing oil out, she does not wear a watch.
great info and good luck to you too fellow shareholder
Nutra Pharma registered with the Defense Commissary Agency and the Base Exchange Services at all active military bases to market their products. In addition, Nutra Pharma has applied for a DAPA (Distribution & Pricing Agreement) with Defense Logistics Agency Philadelphia to market the products directly with any federal agency under this contract vehicle," he continued. "We have also submitted the Nyloxin products to the Army's Fort Dietrich New Products & Ideas Center for evaluation. They have stated that these products fall within the parameters of the program," Mr. Horn concluded.
To all who truly don't understand "pennyland"
NPHC hit a penny today !!!!!!!! Maybe we see .05 soon
lol. im 6'4" and i aint short NPHC either
good call
nt-10q being filed is an extension which by definition means they are not considered late
and when they don't put out news you complain about that
good luck
err umm i meant .03 coming sooon . good call
10-Q will drop today or Monday. Happens all of the time with OTCBB companies
MERQ has been showing 10K but not moving. looks like they are shorting a ton of stick.
thanks greeny stock is up like you predicted. good call. i agree with you i think we see .01 by next week !!!
probably blogworthy
Awesome. thanks for posting. stock should start flying soon i agree with you!
Nutra Pharma Announces Interviews with Wall Street Buy Sell Hold
Nutra Pharma is announcing a recent interview with Chris Castaldo and Wall Street Buy Sell Hold
Business WirePress Release: Nutra Pharma Corporation – 1 hour 13
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--
Nutra Pharma Corporation (NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is the CEO's first in almost two years and outlines the short, mid-term and long-term goals of the company. Castaldo also interviewed Jonathan Flicker, the CEO of Nutra Pharma's new Nyloxin™ Distributor, New Vitality.
“I was happy to have this opportunity to update the public on the Company,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. “We have a lot of great things happening that are coming to fruition over the next few months. This interview provided a perfect forum for letting our shareholders and the public see our present efforts and future goals," he concluded.
The stated goal at Wall Street Buy Sell Hold (WSBSH) is to identify cutting edge growth companies that offer unique products and services. They then alert individual and professional investors about their discoveries.
"Investing in small and micro-cap stocks can be extremely volatile," stated Chris Castaldo, CEO of Wall Street Buy Sell Hold. "However, with the markets indices at or near all time highs, investors are looking elsewhere to achieve above average gains. Recently, I became aware that New Vitality was test marketing the products of Nutra Pharma. After a few phone calls, I found myself in the conference room of New Vitality (Farmingdale, NY), with both Jonathan Flicker and Rik Deitsch for an in-depth interview," he continued. "I believe that we have identified an enormous opportunity and take great pleasure in sharing our findings with the investing public," Castaldo concluded.
In June, Nutra Pharma announced that New Vitality would be test-marketing Nyloxin™, Nutra Pharma's homeopathic treatment for chronic pain. For the past 16 years New Vitality (www.newvitality.com) has helped people live longer and look younger by marketing and selling vitamins, health supplements, and personal care products. Customers learn about their products from advertisements which use celebrities, sport athletes and doctors to promote them on over 2000 radio and television stations nationwide. New Vitality’s catalog contains over 150 items which range from energy supplements to fruit and vegetable supplements to colon cleanses and products for men’s health.
The interview with Rik Deitsch, CEO of Nutra Pharma can be viewed at:
http://tinyurl.com/nutra-interview
The interview with Jonathan Flicker, CEO of New Vitality can be viewed at:
http://tinyurl.com/JF-interview
DMF and FDA registration are different events, both critical.
The FDA is also a difficult registration
HomeFoodDrugsMedical DevicesRadiation-Emitting ProductsVaccines, Blood & BiologicsAnimal & VeterinaryCosmeticsTobacco Products
Drug Establishments Current Registration Site
Print Share E-mail
FDA HomeDrug DatabasesDrug Establishments Current Registration Site
-
New Search
Search Results on Positron Corporation
Displaying records 1 to 1 of 1 Download data Download data
Firm Name Facility
Establishment Identifier Data Universal
Numbering System Number
Address Expiration Date
Positron Corporation 118490259 530 Oakmont Lane, Westmont, Illinois (IL) 60559, United States (USA) 12/31/2013
Data Current through: August 14, 2013
LINK >>>>> http://www.accessdata.fda.gov/scripts/cder/drls/getDRLS.cfm
POSC facility is now registered with the FDA which allows them to sell radio active products.
Go to FDA website to see.
I think there is one big seller cashing out last 2 days.
what is tripps?
They are going forward with it.
"Nyloxin- no marketing firm"Nutra Pharma Announces Radio Campaign for the Marketing of Its All-Natural Pain Reliever, Nyloxin(TM)
New Vitality Is Currently Test-Marketing the Company's Homeopathic, Non-Addictive, Non-Narcotic, Non-Opiate Pain Relieving Product in Radio Advertising Across the United States
Nutra Pharma Announces Licensing Agreement for the Marketing and Distribution of Its All-Natural Pain Reliever, Cobroxin®
Marketing of the Company's homeopathic, non-addictive, non-narcotic, non-opiate pain relieving product to begin in Q3 2013
PR NewswirePress Release: Nutra Pharma Corporation – Mon, Jun 10, 2013 10:07 AM EDT
CORAL SPRINGS, Fla., June 10, 2013 /PRNewswire/ -- Nutra Pharma Corporation (NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company has entered into a licensing agreement with Cobra Pharmaceuticals for the re-launch of their all-natural, non-addictive pain reliever - Cobroxin®, the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain.
The terms of the licensing agreement state that Cobra Pharmaceuticals will be responsible for marketing, distribution, inventory control and customer service of Cobroxin®. They will maintain exclusive rights in perpetuity provided that they maintain minimum quarterly sales that increase over time.
Cobroxin® is a homeopathic drug that utilizes proteins from cobra venom to relieve pain and inflammation. An analgesic that began gaining U.S. attention in 1936, cobra venom's effects in minute doses have been shown by researchers to be superior to that of morphine, a highly addictive opiate. The product is available in an easy-to-use oral spray for treating: lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, as well as a topical gel for treating: repetitive stress, arthritis and joint pain.
3 main products from NPHC
1. Cobroxin recent news on Cobroxin http://finance.yahoo.com/news/nutra-pharma-announces-licensing-agreement-140700746.html
2. Nyloxin website http://mynyloxin.com/content/default.aspx
Recent news on Nyloxin http://finance.yahoo.com/news/nutra-pharma-announces-radio-campaign-163554173.html
3. Pet Pain-Away recent news on Pet Pain-Away http://finance.yahoo.com/news/nutra-pharma-announces-launch-pet-130000838.html
it is getting pounded
I heard there were issue placing buys through Etrade at the open for about a half hour. Anyone else have issues?
Someone is shorting the heck out of PEII
Shorts are screwed SQUEEEEEEZE
PEII daily production expected to rocket to 100 - 200 BO/D by 2nd quarter 2014
Petron Energy II, Inc. Projects It Will Become Profitable in the 2nd Quarter of 2014
MarketwiredPress Release: Petron Energy II, Inc. – 5 minutes ago
DALLAS, TX--(Marketwired - Aug 13, 2013) - Petron Energy II, Inc. ("Petron II" or the "Company") (OTCBB: PEII) projects that it will likely become profitable in the 2nd Quarter of 2014.
Petron Energy II, Inc., together with its subsidiaries, engages in the acquisition and development of properties for the production of crude oil and natural gas, the transportation of natural gas through its pipeline subsidiary and well servicing through its servicing subsidiary. The Company's operations are primarily based in the United States.
Petron Energy II, Inc. is a secondary recovery company, and its game plan is to begin water/gas flood operations on each of its leases to achieve optimal production levels.
Petron Energy II, Inc. projects that if it can continue its current pace of production improvements and successfully earn its second tranche against its $5 million line of credit from TCA Global Credit Master Fund, LP ("TCA"), there is a strong possibility that it will become profitable by late 2nd quarter 2014.
Floyd Smith, President and CEO of Petron Energy II, Inc., states, "We really like how our development plan is materializing. We recently closed on several key leases which are positioned in an area which offers very good production history. Flooding these leases should allow peak daily production rates in the range of 35 - 50 BO/D from each lease after 90 days of flooding procedures. We have 18 leases to implement secondary recovery flooding procedures on."
"Currently, we are working with our funding source, TCA, to structure our second tranche, which should allow us to put 2 - 4 of our leases into full secondary recovery operations. A second tranche of $500,000 - $1,000,000 should allow us to grow our daily production to 100 - 200 BO/D. Our breakeven is achieved at 100 BO/D." Smith further states, "We feel the execution of our plan of secondary recovery operations should increase oil and natural gas production rates significantly. The company is projecting that this significant growth in oil and natural production should allow it to achieve profitability sometime during the latter part of the 2nd quarter 2014."
low float. news send this one flying. load up. stay tuned.